In vitro binding interaction of atorvastatin with calf thymus DNA: multispectroscopic, gel electrophoresis and molecular docking studies

Publication date: Available online 18 August 2018Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Zeinab Mirzaei-KalarAbstractThe interaction of atorvastatin with calf thymus DNA (CT-DNA) was investigated in vitro under simulated physiological conditions by using absorption and emission spectroscopy, viscosity measurements, gel electrophoresis and molecular docking studies. Analysis of UV-Visible absorbance spectra indicates the formation of complex between atorvastatin and CT-DNA, and obtained binding constant (Kb = 8.2×104 L. mol-1) is comparable to groove binder drugs. Slight increase of viscosity of CT-DNA demonstrated the groove binding mode. Hoechst 33258 and methylene blue (MB) displacement studies further confirmed such mode of atorvastatin interaction. Thermodynamic parameters ΔG, ΔH, and ΔS measurements were taken at different temperatures indicated that hydrophobic forces played main role in the binding process. Molecular docking provided detailed computational interaction of atorvastatin with CT-DNA which proved that atorvastatin binds to the groove of CT-DNA. Cleavage experiments showed that atorvastatin does not induce any cleavage under the experimental setup. Finally, all results indicated that atorvastatin interacts with CT-DNA via groove binding mode.Graphical abstract
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research

Related Links:

After controversial guidelines were introduced, cholesterol levels are inching down and more Americans are taking much-needed statin drugs.
Source: Los Angeles Times - Science - Category: Science Authors: Source Type: news
CONCLUSION: Dyslipidemia patients with pre-existing depression had increased risk for CVD. Future studies that determine CVD risk after management of depression among dyslipidemia patients are needed. PMID: 31701694 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - Category: Endocrinology Tags: Diabetes Metab J Source Type: research
The 2013 American College of Cardiology and American Heart Association practice guidelines recommend physicians prescribe HMG-CoA reductase inhibitors (statins) to patients with high cholesterol and to patients with or at high risk for atherosclerotic cardiovascular disease, regardless of cholesterol levels1. According to the National Center for Health Statistics (NCHS), from 2011 to 2012, 1 in 4 adults ages 40 years and older were taking prescription cholesterol lowering medications, 93% of which were statins2.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Regular Research Article Source Type: research
Conclusion: Early rule out protocol is effective and safe.We refer interested readers to the following excellent reviews of high-sensitivity troponin implementation:Twerenbold, R. et al.JACC70 (8): 996 –1012. S. et al. 2016. Am J Med 129 (4): 354 –65. to the 2nd “Myth-busting” articleInterestingly, on Nov 5, Dr. Spiegel publishedanother “Myths in EM” piece in EM News: “Is hs-cTnT Worth the Downstream Testing?. The piece assesses a new randomized trial of the Roche hs -cTnT...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
CONCLUSIONS: No association between ApoB/apoA1 ratio and CVE was found at the baseline visit of patients with RA from the CARMA study. PMID: 31694752 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Words that harm, statins, thyroid replacement, and the ISCHEMIA trial are the topics discussed by Dr John Mandrola in this week ’ s on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Commentary Source Type: news
What have we learned about the effects of long-term statin therapy among this age group? Is it beneficial?Journal of the American Geriatrics Society
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
In patients with diabetes, where cardiovascular morbidity is highly prevalent, recent cardiovascular outcomes trials have identified therapies in the modern glucagon-like peptide 1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) classes that significantly reduce cardiovascular events. A number of drugs in both classes have demonstrated reductions in the risk of the composite outcome of major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death). In addition, SGLT2i drugs have a substantial impact on hospitalization for heart failure. Because GLP-1RA and SGL...
Source: Cardiovascular Endocrinology - Category: Cardiology Tags: Review Articles Source Type: research
Conclusions. Our data suggests that hsa-miR-24-3p might have an effect on CYP4F2 activity during atherosclerosis. PMID: 31694408 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research
Evidence from observational studies have found a relationship between serum cholesterol and diabetic retinopathy (DR). Apart of the assumption that cholesterolemic control has benefits for patients with diabet...
Source: Diabetology and Metabolic Syndrome - Category: Endocrinology Authors: Tags: Review Source Type: research
More News: Atorvastatin Calcium | Drugs & Pharmacology | Lipitor | Statin Therapy | Study | Zivast